- Home
- ANVS vs CGTX Comparison
ANVS vs CGTX Comparison
Compare ANVS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | CGTX |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 94.5M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANVS | CGTX |
|---|---|---|
| Price | $2.50 | $1.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $13.50 | $3.33 |
| AVG Volume (30 Days) | 306.4K | ★ 624.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.22 |
| 52 Week High | $5.50 | $3.83 |
Technical Indicators
Market Signals| Indicator | ANVS | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 52.08 |
| Support Level | $2.27 | $1.00 |
| Resistance Level | $2.63 | $1.19 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 21.54 | 80.56 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.